Risco de Sarcopenia em Pacientes Oncológicos em Tratamento Quimioterápico

Bárbara Garcia Figueredo; Vanessa de Mello  Konzen; Lia Mara Wibelinger; Matheus Santos Gomes Jorge; Gabriela Schneider; Ionara de Oliveira Mota; Stephani Garbin

doi:10.32635/2176-9745.RBC.2026v72n2.5574

Authors

Bárbara Garcia Figueredo Universidade de Passo Fundo (UPF), Programa de Residência Multiprofissional Integrada em Saúde – Ênfase em Atenção ao Câncer. Passo Fundo (RS), Brasil. https://orcid.org/0000-0002-8577-0906
Vanessa de Mello Konzen UPF. Passo Fundo (RS), Brasil. https://orcid.org/0000-0001-5408-9598
Lia Mara Wibelinger UPF, Curso de Fisioterapia. Passo Fundo (RS), Brasil. https://orcid.org/0000-0002-7345-3946
Matheus Santos Gomes Jorge UPF, Curso de Fisioterapia. Passo Fundo (RS), Brasil. https://orcid.org/0000-0002-4989-0572
Gabriela Schneider Universidade de Passo Fundo (UPF), Programa de Residência Multiprofissional Integrada em Saúde – Ênfase em Atenção ao Câncer. Passo Fundo (RS), Brasil. https://orcid.org/0000-0001-8550-968X
Ionara de Oliveira Mota Universidade de Passo Fundo (UPF), Programa de Residência Multiprofissional Integrada em Saúde – Ênfase em Atenção ao Câncer. Passo Fundo (RS), Brasil. https://orcid.org/0009-0000-1480-282X
Stephani Garbin Universidade de Passo Fundo (UPF), Programa de Residência Multiprofissional Integrada em Saúde – Ênfase em Atenção ao Câncer. Passo Fundo (RS), Brasil. https://orcid.org/0000-0003-0603-5506

DOI:

https://doi.org/10.32635/2176-9745.RBC.2026v72n2.5574

Keywords:

Inpatients, Neoplasms, Antineoplastic Agents/radiation effects, Sarcopenia

Abstract

Introduction: Chemotherapy treatment can cause several direct and indirect side effects on muscle tissue. Sarcopenia is related to decreased strength, chemotoxicity, decreased functional performance, increased fatigue, lower tolerance to treatments, postoperative complications, age, and low survival in some types of cancer. Objective: Analyze the risk of sarcopenia in hospitalized individuals with cancer undergoing chemotherapy. Method: This is a descriptive, cross-sectional study with adult and elderly individuals undergoing cancer treatment in two high- complexity hospitals in Southern Brazil. Sociodemographic conditions were collected using a questionnaire, in addition to performing the handgrip strength test using manual dynamometry and assessing the risk of sarcopenia using the SARC-CalF. Results: This study included 131 individuals, in which the prevalence of sarcopenia risk among hospitalized cancer patients undergoing chemotherapy was 55.7%. Regarding the predominance of individuals at risk for sarcopenia, the following variables were observed: 60 years or older (68.9%), non-white race (84%), individuals with incomplete secondary education (62.9%), retired (67.6%), palliative care (76%), and sedentary or irregularly active individuals (61.1%). Conclusion: Hospitalized cancer patients undergoing chemotherapy presented a high prevalence of sarcopenia risk.

Downloads

Download data is not yet available.

References

Instituto Nacional do Câncer [Internet]. Rio de Janeiro: INCA, 2022. O que é câncer? 2022 maio 31 [acesso 2025 nov 15]. Disponível em: https://www.gov.br/inca/pt-br/assuntos/cancer/o-que-e-cancer/o-que-e-cancer

Medeiros GOC, Rocha IMG, Marcadenti A, et al. The additional benefit of computed tomography in cancer patients: impacts of sarcopenia and cachexia on quality of life during chemotherapy. Radiol Bras. 2024;57:e20240012. doi: https://doi.org/10.1590/0100-3984.2024.0012 DOI: https://doi.org/10.1590/0100-3984.2024.0012

Williams GR, Dunne RF, Giri S, et al. Sarcopenia in the older adult with cancer. J Clin Oncol. 2021;39(19):2068- 78. doi: https://doi.org/10.1200/JCO.21.00102 DOI: https://doi.org/10.1200/JCO.21.00102

Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636-46. doi: https://doi.org/10.1016/s0140-6736(19)31138-9 DOI: https://doi.org/10.1016/S0140-6736(19)31138-9

Silva HKM, Cavalcante LS, Almeida GAS, et al. Risco de sarcopenia e toxicidade gastrointestinal de pacientes idosos em quimioterapia. Rev Bras Cancerol. 2024; 70(2):e-054606. doi: https://doi.org/10.32635/2176-9745.RBC.2024v70n2.4606 DOI: https://doi.org/10.32635/2176-9745.RBC.2024v70n2.4606

Bossi P, Delrio P, Mascheroni A, et al. The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients. 2021;13(6):1980. doi: https://doi.org/10.3390/nu13061980 DOI: https://doi.org/10.3390/nu13061980

Lima AB, Ribeiro GS, Henriques-Neto D, et al. Desempenho diagnóstico do SARC-F e do SARC-CalF na triagem de sarcopenia em idosos no Norte do Brasil. Sci Rep. 2023;13:11698. doi: https://doi.org/10.1038/s41598-023-39002-y DOI: https://doi.org/10.1038/s41598-023-39002-y

Conselho Nacional de Saúde (BR). Resolução no 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos [Internet]. Diário Oficial da União, Brasília, DF. 2013 jun 13. [acesso 2025 out 14]; Seção 1:59. Disponível em: https://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html

Vega MCMD, Laviano A, Pimentel GD. Sarcopenia e toxicidade mediada pela quimioterapia. Einstein. 2016;14(4):580-4. doi: https://doi.org/10.1590/s1679-45082016md3740 DOI: https://doi.org/10.1590/s1679-45082016md3740

Zangalli I, Cordova BF, Zanotti J. Avaliação da sarcopenia e fatores associados em pacientes oncológicos de uma associação de apoio a pessoas com câncer de Caxias do Sul/RS. Braz J Hea Rev. 2022;5(1):2477-90. doi: https://doi.org/10.34119/bjhrv5n1-221 DOI: https://doi.org/10.34119/bjhrv5n1-221

Bozzetti F. Age-related and cancer-related sarcopenia: is there a difference? Curr Opin Clin Nutr Metab Care. 2024;27(5):410-8. doi: https://doi.org/10.1097/mco.0000000000001033 DOI: https://doi.org/10.1097/MCO.0000000000001033

Williams GR, Deal AM, Schachar SS, et al. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol. 2018;81(2):413-17. doi: https://doi.org/10.1007/s00280-017-3487-2 DOI: https://doi.org/10.1007/s00280-017-3487-2

Fabiano LC, Buttow NC. Sarcopenia e quimioterapia: efeitos do 5-fluorouracil e a importância do exercício físico. Cuad Ed Desar. 2024;16(11):e6226. doi: https://doi.org/10.55905/cuadv16n11-017 DOI: https://doi.org/10.55905/cuadv16n11-017

Xu XY, Jiang XM, Xu Q, et al. Skeletal muscle change during neoadjuvant therapy and its impact on prognosis in patients with gastrointestinal cancers: a systematic review and meta-analysis. Front Oncol. 2022;12:892935. doi: https://doi.org/10.3389/fonc.2022.892935 DOI: https://doi.org/10.3389/fonc.2022.892935

Tzeng PL, Lin CY, Lai TF, et al. Daily lifestyle behaviors and risks of sarcopenia among older adults. Arch Public Health. 2020;78(1):113. doi: https://doi.org/10.1186/s13690-020-00498-9 DOI: https://doi.org/10.1186/s13690-020-00498-9

Klassen PN, Baracos V, Ghosh S, et al. Muscle and adipose wasting despite disease control: unaddressed side effects of palliative chemotherapy for pancreatic cancer. Cânceres. 2023;15(17):4368. doi: https://doi.org/10.3390/cancers15174368 DOI: https://doi.org/10.3390/cancers15174368

Queiroz MSC, Wiegert EVM, Lima LC, et al. Associação entre sarcopenia, estado nutricional e qualidade de vida em pacientes com câncer avançado em cuidados paliativos. Rev Bras Cancerol. 2018;64(1):69- 75. doi: https://doi.org/10.32635/2176-9745.RBC.2018v64n1.120 DOI: https://doi.org/10.32635/2176-9745.RBC.2018v64n1.120

Sánchez-Sánchez JL, Mañas A, García-García FJ, et al. Sedentary behaviour, physical activity, and sarcopenia among older adults in the TSHA: isotemporal substitution model. J Cachexia Sarcopenia Muscle. 2019;10(1):188-98. doi: https://doi.org/10.1002/jcsm.12369 DOI: https://doi.org/10.1002/jcsm.12369

Steffl M, Bohannon RW, Sontakova L, et al. Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017;12:835-45. doi: https://doi.org/10.2147/cia.s132940 DOI: https://doi.org/10.2147/CIA.S132940